SBP Group's M701 Bispecific Antibody Receives NDA Acceptance for Malignant Ascites Treatment
Key Insights
SBP Group's subsidiary Chia Tai Tianqing Pharmaceutical (search) has received NDA acceptance from China's CDE for M701, a CD3/EpCAM bispecific antibody (search) targeting malignant ascites (search).
M701 represents China's first independently developed CD3/EpCAM bispecific antibody (search), designed to simultaneously target EpCAM (search) on tumor cells and CD3 (search) on immune T cells.
The innovative drug activates T cells to kill tumor cells by forming a bridge between tumor cells and immune T cells through dual-target binding.
SBP Group announced that China's Center for Drug Evaluation (CDE) has accepted the new drug application (NDA) for M701, a CD3/EpCAM bispecific antibody (search) developed by its subsidiary Chia Tai Tianqing Pharmaceutical (search) Group Co. Ltd. (CTTQ). The innovative drug is being developed for the treatment of malignant ascites (search) caused by advanced epithelial malignancies (search).
First-in-Class Bispecific Antibody Technology
M701 represents a significant milestone as China's first independently developed CD3/EpCAM bispecific antibody (search). The drug employs a dual-targeting mechanism, simultaneously binding to EpCAM (search) on tumor cells and CD3 (search) on immune T cells. This innovative approach creates a bridge between tumor cells and immune T cells through dual-target binding, ultimately activating T cells to eliminate tumor cells.
The bispecific antibody design represents an advancement in cancer immunotherapy, leveraging the body's immune system to target malignant cells more effectively than traditional single-target approaches.
Expanding Pipeline Success
This NDA acceptance adds to SBP Group's recent regulatory achievements across multiple therapeutic areas. The company has demonstrated consistent progress with several innovative drugs in its pipeline:
The group recently received approval from the Guangdong Medical Products Administration for naldemedine's early launch in the Guangdong-Hong Kong-Macao Greater Bay Area for treating opioid-induced constipation (search). Additionally, culmerciclib capsules, a CDK2/4/6 inhibitor (search), received approval from China's National Medical Products Administration for a second indication in hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer (search) when combined with fulvestrant.
Clinical Development Progress
Beyond M701, SBP Group's wholly-owned subsidiary LaNova Medicines Limited has initiated a Phase III registrational clinical trial for cafelkibart (LM-108), a CCR8 monoclonal antibody (search) for gastric cancer (search), with the first patient successfully enrolled. The company has also received FDA approval for investigational new drug application for TQB3205 (search), a pan-KRAS inhibitor (search), for treating advanced malignant tumors.
Market Position
M701's classification as a national Category 1 innovative drug underscores its potential significance in addressing unmet medical needs in oncology. The acceptance of the NDA represents a critical step toward potential commercialization of this first-in-class bispecific antibody therapy for patients with malignant ascites (search) caused by advanced epithelial malignancies (search).